Fig. 3.

Oxygen requirements and SpO₂/FiO₂ratios of patients receiving rhDNase. Severely ill patients with COVID-19 that required high-flow nasal oxygen (HFNO) or conventional oxygen therapy (COT) (n = 5) were treated with aerosolized rhDNase (TP1–5). Dashed vertical line at the center of the graph denotes start of rhDNase treatment. Oxygen flow rate (A) and estimated SpO₂/FiO₂ ratio (B) of patients receiving HFNO therapy at the time of rhDNase treatment start. Solid lines are flow rate during HFNO, whereas dashed lines are flow rate during COT. Asterisks indicate hospital discharge. COVID-19, coronavirus disease 2019; FiO₂, fraction of inspired oxygen; rhDNase, recombinant human DNase I; SpO₂, the oxygen saturation as measured by pulse oximetry.